Tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma

被引：0

作者：

Yoon, Harry H.

Kato, Ken

Hubner, Richard

Raymond, Eric

Tao, Aiyang

Liu, Sumei

Qazi, Ibrahim

Xu, Jian-Ming

机构：

[1] Mayo Clin, Rochester, MN USA

[2] Natl Canc Ctr, Tokyo, Japan

[3] Christie NHS Fdn Trust, Manchester, Lancs, England

[4] Ctr Hosp Paris St Joseph, Paris, France

[5] BeiGene USA, San Mateo, CA USA

[6] BeiGene Beijing Co Ltd, Beijing, Peoples R China

[7] Chinese Peoples Liberat Army PLA Gen Hosp, Med Ctr 5, Beijing, Peoples R China

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS462

引用

页数：2

共 50 条

[1] SHR-1701 plus chemotherapy as first-line treatment for unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).
Wang, Yi
Liu, Hong
Wang, Qingwei
Qiao, Naian
Wang, Jianbo
Tan, Bingxu
Cheng, Bo
Chu, Yunxia
Li, Huajun
Cheng, Yufeng
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 363 - 363
[2] Cost-Effectiveness Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China
Zhou, Chongchong
Wei, Jingxuan
Xu, Kai
Lin, Yingtao
Zhang, Lingli
Li, Xin
RISK MANAGEMENT AND HEALTHCARE POLICY, 2023, 16 : 2447 - 2458
[3] Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China
Liu, Yanhong
Shao, Rong
FRONTIERS IN PHARMACOLOGY, 2024, 15
[4] Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma
Xu, Jianming
Bai, Yuxian
Xu, Nong
Li, Enxiao
Wang, Buhai
Wang, Jin
Li, Xiang
Wang, Xin
Yuan, Xianglin
CLINICAL CANCER RESEARCH, 2020, 26 (17) : 4542 - 4550
[5] A randomized, placebo-controlled, phase III trial-in-progress to evaluate the efficacy and safety of tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma (ESCC).
Xu, Jian-Ming
Kato, Ken
Hubner, Richard
Raymond, Eric
Xu, Yihuan
Liu, Sumei
Qazi, Ibrahim
Yoon, Harry H.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[6] GEMSTONE-304: A phase 3 study of sugemalimab plus chemotherapy versus chemotherapy as first-line treatment of patients with unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC)
Li, J.
Chen, Z.
Bai, Y.
Liu, B.
Li, Q.
Zhou, J.
Zhang, J.
Deng, T.
Zhou, F.
Gao, S.
Yang, S.
Ye, F.
Chen, L.
Bai, W.
Yin, X.
Xu, Y.
Hu, J.
Ni, J.
Wang, B.
Yang, J.
ANNALS OF ONCOLOGY, 2023, 34 : S181 - S182
[7] Efficacy and safety of KN046 plus paclitaxel/cisplatin as first-line treatment for unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).
Xu, Jianming
Liu, Rongrui
Zhang, Yanqiao
Xu, Nong
Fan, Qingxia
Gao, Shegan
Pan, Hongming
Cai, Mingquan
Yan, Dong
Liang, Qianqian
Wu, Qiong
Guo, Baohong
Qi, Yakun
Xu, Ting
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[8] Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for locally advanced/metastatic nonsquamous NSCLC
Lu, S.
Yu, Y.
Yu, X.
Hu, Y.
Ma, Z.
Li, X.
Zhuang, W.
Liu, Y.
Li, W.
Cui, J.
Wang, D.
Liao, W.
Wang, M.
Zhou, J.
Wang, Z.
Sun, Y.
Gao, J.
Bao, Y.
Liang, L.
Wang, J.
ANNALS OF ONCOLOGY, 2020, 31 : S816 - S817
[9] Safety and efficacy of tislelizumab plus chemotherapy for first-line treatment of advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma
Qiu, Hai-Bo
THORACIC CANCER, 2020, 11 (12) : 3419 - 3421
[10] Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in China
He, Chaoneng
Mi, Xiufang
Xu, Gaoqi
Xu, Xinglu
Xin, Wenxiu
Zhong, Like
Zhu, Junfeng
Shu, Qi
Fang, Luo
Ding, Haiying
PLOS ONE, 2024, 19 (05):

← 1 2 3 4 5 →